Biography:David Charles Rees
David Charles Rees | |
|---|---|
 David Charles Rees | |
| Alma mater | University of Southampton (BSc), University of Cambridge (PhD) |
| Known for | Astex |
| Awards | Royal Society of Chemistry, Malcolm Campbell Award 2007[1] |
| Scientific career | |
| Fields | Drug discovery, Medicinal chemistry, Organic chemistry |
| Institutions | Astex, AstraZeneca, Organon |
| Thesis | A new approach to the synthesis of aspidosperma alkaloids using tricarbonylcyclohexadienylium iron intermediates[2] |
| Website | astx |
David Charles Rees (born 1958) CChem, FRSC is a chemist whose main research interest is discovering new medicines.[3] He is Chief Scientific Officer at Astex Pharmaceuticals Cambridge UK,[4] a biotechnology company focussed on Fragment Based Drug Discovery. In 2003 David was hired by Astex to lead the chemistry team, and became Chief Scientific Officer in 2017.[5] Three anti-cancer agents were created in research involving David: ribociclib (Astex Novartis collaboration)[6] and erdafitinib (Astex Janssen collaboration)[7] and the anaesthetic agent sugammadex (Organon, Merck)[8] which had global sales of US$917 million in 2018.[9] David was President of the Organic Division from 2010 to 2013 of the Royal Society of Chemistry and was later elected as a Trustee of the RSC (2015-2019).[10] He is a Director of Ashanti Development, a charity that promotes clean water and sanitation in Ghana.[11]
References
- ↑ "BMCS Malcolm Campbell Award". https://www.rsc.org/Membership/Networking/InterestGroups/BMCS/Activities/CampbellAward.asp.
- ↑ "e-theses online service". https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.331758.
- ↑ "david rees - Google Scholar Citations". https://scholar.google.co.uk/citations?hl=en&user=0FZmyzQAAAAJ.
- ↑ "Astex – Oncology and CNS Drug Discovery & Development". https://astx.com/.
- ↑ "David Rees – Astex". https://astx.com/portfolio-item/david-rees/.
- ↑ Bickerton, Peggy. "Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval – Astex". https://astx.com/cambridge-based-astex-pharmaceuticals-celebrates-as-cancer-drug-receives-us-marketing-approval/.
- ↑ webadmin. "Astex Pharmaceuticals Celebrates as Second New Cancer Drug Receives US Marketing Approval – Astex". https://astx.com/astex-pharmaceuticals-celebrates-as-second-new-cancer-drug-receives-us-marketing-approval/.
- ↑ Bom, Anton; Bradley, Mark; Cameron, Ken; Clark, John K.; Egmond, Jan van; Feilden, Helen; MacLean, Elizabeth J.; Muir, Alan W. et al. (2002). "A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host". Angewandte Chemie International Edition 41 (2): 265–270. doi:10.1002/1521-3773(20020118)41:2<265::AID-ANIE265>3.0.CO;2-Q. ISSN 1521-3773.
- ↑ "Merck & Co., Inc. Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2018". https://s21.q4cdn.com/488056881/files/doc_financials/2018/Q4/2018-Form-10-K-(without-Exhibits)_FINAL_022719.pdf.
- ↑ "The Royal Society of Chemistry - our structure". https://www.rsc.org/about-us/our-structure/.
- ↑ "Our Team in the UK". https://ashantidevelopment.org/our-story/our-team-in-the-uk/.
 |
